RecruitingObesityOverweight

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Eligible age

18+ yrs

Accepts

All genders

Locations

23 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Sponsor: Eli Lilly and Company

You may qualify if…

✓ Have Body Mass Index (BMI) at screening of the following:
✓ 30 kilogram per square meter (kg/m2) OR
✓ 27 kg/m2 with at least one of the following weight-related health conditions at screening:
✓ high blood pressure
✓ dyslipidemia
✓ obstructive sleep apnea, or
✓ heart disease
✓ Have a stable body weight (\<5% body weight change) for 90 days prior to screening.

You may not qualify if…

✕ Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
✕ Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
✕ Have type 1 diabetes or type 2 diabetes
✕ Have had within 90 days prior to screening:
✕ heart attack
✕ stroke
✕ coronary artery revascularization
✕ unstable angina, or